Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies

NCT04475523 is registered in ClinicalTrials.gov with Curis, Inc. as lead sponsor.

NCT NCT04475523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04475523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies
Lead sponsor
Curis, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 22, 2020
Completion date
May 19, 2023
Enrollment
26 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor